Smart, color-changing sanitary pads that detect increased protein in urine (a sign of preeclampsia) early.
Patent Information
- Application Number
- TR202615111
- Authority / Receiving Office
- TR · TR
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2026-09-04
- Publication Date
- 2026-09-21
Smart Images
Figure 00000006_0000
Abstract
Description
1 TARIFF Increased Protein Levels in Urine (a Sign of Preeclampsia) - Early Detection by Color Replaceable Smart Hygiene Pad TECHNICAL AREA 5 The invention relates to medical diagnostic / in vitro diagnostic products, particularly hygiene pads and similar items. Daily hygiene products are integrated into the urinary components. (protein / albumin) colorimetric method analysis enables gy leb lr diagnostics. The area of the conditions is related to this. More specifically, the meeting occurs after the 20th week of pregnancy. In pregnant women at risk for preeclampsia, clinically significant protein deficiency is observed. By evaluating the amount of protein in the urine together with creatinine (urine protein / creatinine ratio [PCR] based, using an indicator threshold) Developed to aid in scanning, these color-changing, wearable smart devices br ped düzeneğ ne l şk nd r. STATE OF THE ART Nowadays, to determine protein levels (presence of protein in urine) during pregnancy, a sample of the woman's urine is taken. For example, a sample is taken in a coarse manner and a separate test strip (d p-st ck) is dipped into this sample. Classical methods are based on the observation of color changes. It is used. For this purpose, tetrabromophenol (MAV SGB protein) error 20 is used in the market. Free urine test strips containing indicators (Protein Error of Indicators). It is located there. Also, protein n-only d pst ck test nn urine dilution nden Due to its effect, it measures both protein and creatinine on a single strip. There are also commercial products (e.g., Simensin) that give an approximate protein / creatinine ratio (PCR). Mult st x PRO LS, L feAssay D agnost cs Pr / Cr şer d ) are present. However, this type 25 The swabs are also collected in a separate sample container and by hand in a laboratory or healthcare facility. Immersion requires a process; spontaneously, in daily and private settings. applications integrated into the product that can be used It is not known. During pregnancy, the woman's belly grows, causing her to bend over, and the urine... 30 Holding the container and collecting daily samples becomes physically difficult; the process During this process, urine can contaminate hands and the environment. Also in rural areas... Pregnant women who are alive should go to the hospital / laboratory every day to get tested. 2 This is not practically possible; these repeated hospital visits require transportation and time. In terms of loss and healthcare costs, both pregnant women and children, as well as healthcare professionals, This creates additional costs for the system. Therefore, preeclampsia (pregnancy) Protein poisoning, an early sign of which is not detected in time, Diagnosis is delayed. The main direct causes of maternal deaths in Turkey are 5 among them are bleeding, preeclampsia / eclampsia (pregnancy poisoning) and infection. It ranks among the leading causes of death; late detection of preeclampsia is a preventable risk to both mother and child. Infant mortality is one of the leading causes of death. DESCRIPTION OF THE INVENTION 10 The aim of this invention is to analyze urine components (protein / albumin) using colorimetric methods. The goal is to develop diagnostic strips that enable the detection of ed lmes n. The invention concerns the arrangement of sanitary pads / strips, which are already in daily use. h jyen k ped n ç ne, dış içinde g z l br prote n hata nd katör şer d This allows for placement. Thus, the woman also needs a sample collection container. 15 without hearing, without taking a sample, without disrupting the daily routine, spontaneously The resulting test result is displayed through the transparent viewing window on the lower layer of the ped. It can be seen. Chemical indicator strip, microchannels and semipermeable membrane. Thanks to this, it does not come into direct contact with the skin; this eliminates the risk of irritation. The most Importantly, the woman should only go to the hospital if she notices a suspicious color change. Applying for medical attention is sufficient; there is no need to repeatedly visit the hospital for daily routine check-ups. This eliminates the need for transportation and saves time for both pregnant women and their families. This reduces both financial losses and healthcare costs, as well as unnecessary burdens on healthcare institutions. The application load will be reduced. Especially for those living in rural areas or who frequently visit the hospital. Including pregnant women who do not say g, every pregnant woman is one of the leading causes of maternal deaths in Turkey (25%). One of the direct causes is preeclampsia, which is an early and continuous risk factor. It can be monitored at a low cost; this also prevents bleeding and infection. It contributes to reducing maternal / infant mortality. Figure Description 30 Figure 1. Schematic representation of the system. 3 Reference List 1. Pad body (outer casing) 2. Adhesive wings 3. Top layer (em c surface) 4. Middle layer (microchannels) 5 5. Test layer 5a. Protein 5b. Creatine 6. Bottom layer (sealing bar area) 7. Observation window 10 8. Fixed reference color scale DETAILED DESCRIPTION OF THE INVENTION In this detailed explanation, the subject of the invention is the increase in protein in the urine (preeclampsia). (The finding) is related to smart hygiene pads that change color and detect early, and only 15 It contains explanations aimed at a better understanding of the subject and in no way The limiting BRN wire does not carry a wire. The invention, a hygiene pad / strip arrangement, consists of the following layers: Upper Layer (3): The layer that comes into contact with the woman's skin, allowing urine to pass through but not to the bottom. Non-releasing soft E-C surface. 20 Middle Layer: Microchannels that absorb urine and direct it to the underlying test layer. the resulting carrier layer. Test Layer (5): Protein / creatinine ratio consisting of two separate reactant regions (PCR) substantive test shar d . (a) Protein region: Tetrabromophenol blues, bromophenol blues, urinary protein containing at least one of bromocresol green or their derivatives 25 (b) At least one protein defect indicator that changes color when in contact with (album n). Creatinine region: The area in the urine that reacts with creatinine, changing its color. at least one creatine indicator with chemical properties (e.g., Jaffe reaction-based creatine derivatives) or equivalent creatinine indicator). The combined evaluation of these two regions, Compared to the classic KD PST CK method which measures protein alone, 30% of urine... Reducing the risk of false results due to dilution / density, approximately It provides an indicator of the protein / creatinine ratio. On the strips, the upward movement of chemicals is shown. a semi-constrictor that prevents the urine from passing through properly but allows it to drain downwards. 4 A permeable membrane is present. Indicator concentrations are used in the literature. PCR thresholds in the indicator n (although they vary between studies) (approximately 0.15-0.3 range) the color change becomes more pronounced in a nearby area. It has been adjusted with the aim of reducing the interpretation of intermediate tones, as much as possible. The aim was to achieve the sharpest possible NBR transition behavior. 5 Bottom Layer: Acts as a sealing bar and causes color changes on the strip. a transparent viewing window that allows the user to see base layer. Reference Color Scale: Located right next to the viewing window, on the pad. 10 Printed and fixed color scale. The user selects the color in the viewing window from this fixed scale. by directly comparing it side-by-side with a reference, to memory or subjective interpretation You can evaluate the result without hesitation. This solution works with any smartphone. Because it does not require an application or internet connection, it can also be used in rural areas. It can be used without any problems. 15 Working principle b: Urine sample, protein and creatinine regions also come into contact with the nnks. The protein / creatinine ratio is a threshold used in the literature as an indicator of quality. When it falls below the range, at least the indicators in the test layer show a distinct color. It shows no change and remains in a yellow tone. When the ratio rises above this range... Indicators darken clearly and distinctly (green / blue). User, ped 20 When removing it at the end of daily use, the color next to the viewing window by directly comparing the result with the fixed reference color scale provided. This way, the result is not dependent on memory or subjective interpretation. If there is a suspected or positive result, a healthcare facility can be consulted if necessary. 30
Claims
REQUESTS 1. The invention is a smart hygiene pad, characterized by its two separate reactive zones. At least one test integrated into the pad based on protein / creatine ratio (PCR) layer (5), contact of this test layer (5) with drardak prote n (album n). at least one protein defect indicator (5a) that changes color when ett ğ and in the urine 5 at least one creatine that changes color by reacting with creatine (5b) nd katörü çermes le karakter zed r.
2. The gbbr invention in claim 1 has the property that the protein (5a) region tetrabromophenol blue, bromophenol blue, bromocresol green or thereof It is characterized by containing at least one of its derivatives. 10 3. The gbbr invention in claim 1 has the property that the creatinine (5b) nd kator is Jaffe reaction-based p krat derivatives or equivalent br kreat nn indicator The character of Çermes is damaged.
4. The GBBR invention in Claim 1 is characterized by its function as a leak-proof bar. layer (6) and the test layer (5) color 15 located in this sublayer (6). a transparent interface that allows the changes to be seen by the user The viewing window (7) is characterized by its surroundings.
5. The invention in claim 4 is the feature of the viewing window (7). along with, on the pad or on the packaging, the color scale (8) is not included le character zed r. 20 6. The gbbr invention in claim 1 has the property of being a protein defect indicator (5a) and creatinine and inductor (5b) concentrations of 0.15-0.3 protein / creatinine the color change becomes more pronounced in a region close to the ratio range It is characterized by being adjusted in a way that will provide a certain level of character.
7. The GBBR invention in Claim 1 has the characteristic of; on the strips, chemicals 25 prevents the urine from passing upwards but allows it to drain downwards. It is characterized by its semi-transparent, translucent membrane containing zinc.
8. The gbbr invention in claim 1 has the following feature; test layer (5) directing, containing a middle layer (4) consisting of microchannels character zed r. 30 9. Claim 1 describes the GBBR invention, which is characterized by its ability to transmit urine to lower layers and back again. The upper layer (3) that does not release is characterized by its inclusion.